Longevity Science Picks up Steam in Pharma

Why It Matters

The influx of capital and big‑pharma expertise signals a rapid commercialization of age‑targeted therapies, potentially expanding the $8 trillion longevity market by 2030. Successful trials could reshape treatment paradigms for neurodegeneration, vision loss, and other age‑related conditions.

Key Takeaways

• Life Biosciences' ER‑100 starts human trials, first epigenetic reprogramming therapy
• Retro Biosciences and Lysoway launch Phase 1 neurodegeneration candidates
• Private funding hits $8.5 billion, double since 2024
• Novartis signs $550 million BioAge deal for aging data
• GLP‑1 drugs positioned as first proven longevity medicines

Pulse Analysis

The past year has seen longevity research shed its niche label and enter the drug‑development mainstream. Companies like Life Biosciences are pioneering epigenetic reprogramming with ER‑100, a therapy that aims to reset cellular age without altering DNA. Parallel efforts at Retro Biosciences and Lysoway focus on boosting autophagy, the cell’s recycling system, to combat neurodegeneration. By targeting the biological mechanisms that accelerate disease with age, these programs promise more precise interventions than traditional symptom‑based treatments.

Capital flows reflect this scientific momentum. Private investors have poured $8.5 billion into the sector since 2024, more than doubling previous levels, while the market’s valuation is projected to hit $8 trillion by 2030. Big‑pharma is responding with sizable partnerships: Novartis committed up to $550 million to BioAge for access to human longevity datasets, and Eli Lilly is collaborating on undisclosed targets. AI is also becoming a cornerstone, as Insilico Medicine and Human Life Foundation Models launch a multi‑million‑dollar co‑development pact to build large‑scale models that decode aging pathways, accelerating target identification and reducing R&D timelines.

Clinically, the field may already have its first longevity drugs in the form of GLP‑1 agonists, which have demonstrated cardiovascular and neuroprotective benefits that align with multiple aging hallmarks. As early safety data from ER‑100 and Phase 1 readouts from Retro Biosciences emerge later this year, regulators and investors will watch closely for signals that these therapies can translate laboratory insights into approved medicines. Successful outcomes could trigger a cascade of approvals, cementing longevity science as a core pillar of future pharmaceutical pipelines.